Is Mitotane reimbursable?

Mitotane (Mitotane) is an innovative drug for the treatment of adrenocortical cancer (adrenal cancer). It has been approved for marketing in China and is available to patients in the form of an original drug. Its main specifications are 500 mg*100 tablets per box, and the market price is about more than 9,000 yuan, which is still a large expense for most long-term treatment patients. Regarding the issue of medical insurance reimbursement, mitotane is currently not included in the domestic national medical insurance directory, which means that patients must bear all costs of using the drug out of their own pocket. The main reason is that mitotane is a rare disease drug and has been on the market for a relatively short time in China. It has not yet undergone a complete pharmacoeconomic evaluation and medical insurance negotiation process.

In addition, because mitotane is a long-term maintenance medication, its price and treatment cost are relatively high. Medical insurance departments usually need to comprehensively evaluate the actual clinical value of the drug, the size of the patient population, and the economic burden before considering it for inclusion in the catalog. In reality, if patients want to reduce financial pressure, they can pay attention to patient assistance programs and clinical trial opportunities provided by hospital pharmacies or pharmaceutical companies. Such programs can provide drug support to a certain extent or reduce out-of-pocket burdens.

Rare disease drugs are often priced on the high side in the early stages of their launch, and medical insurance coverage and reimbursement policies require a certain period of evaluation and data accumulation. A similar model may be followed in China. At the same time, patients need to weigh efficacy, drug accessibility and affordability when choosing treatment options to ensure the sustainability of long-term medication and continuity of treatment.

Generally speaking, mitotane is already on the market in China, but it is currently not reimbursable through medical insurance. Patients should evaluate their financial affordability in advance when planning long-term treatment, and discuss the most appropriate dosage and treatment schedule with their attending doctor to ensure continuity and safety of treatment, and try to use feasible drug assistance channels to reduce financial pressure.

Reference materials:https://go.drugbank.com/drugs/DB00648